Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
133.41
-3.71 (-2.71%)
At close: Mar 28, 2025, 4:00 PM
132.01
-1.40 (-1.05%)
Pre-market: Mar 31, 2025, 8:31 AM EDT
Repligen Employees
Repligen had 1,778 employees as of December 31, 2024. The number of employees decreased by 5 or -0.28% compared to the previous year.
Employees
1,778
Change (1Y)
-5
Growth (1Y)
-0.28%
Revenue / Employee
$356,827
Profits / Employee
-$14,350
Market Cap
7.49B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,778 | -5 | -0.28% |
Dec 31, 2023 | 1,783 | -242 | -11.95% |
Dec 31, 2022 | 2,025 | 173 | 9.34% |
Dec 31, 2021 | 1,852 | 724 | 64.18% |
Dec 31, 2020 | 1,128 | 367 | 48.23% |
Dec 31, 2019 | 761 | 213 | 38.87% |
Dec 31, 2018 | 548 | 72 | 15.13% |
Dec 31, 2017 | 476 | 240 | 101.69% |
Dec 31, 2016 | 236 | 68 | 40.48% |
Dec 31, 2015 | 168 | 32 | 23.53% |
Dec 31, 2014 | 136 | 20 | 17.24% |
Dec 31, 2013 | 116 | -4 | -3.33% |
Dec 31, 2012 | 120 | -17 | -12.41% |
Dec 31, 2011 | 137 | 69 | 101.47% |
May 6, 2010 | 68 | -1 | -1.45% |
May 31, 2009 | 69 | 13 | 23.21% |
May 27, 2008 | 56 | 11 | 24.44% |
Jun 30, 2007 | 45 | 2 | 4.65% |
Jun 6, 2006 | 43 | 6 | 16.22% |
Jun 7, 2005 | 37 | -3 | -7.50% |
Jun 7, 2004 | 40 | -4 | -9.09% |
May 15, 2003 | 44 | 5 | 12.82% |
May 15, 2002 | 39 | -1 | -2.50% |
May 15, 2001 | 40 | 13 | 48.15% |
May 15, 2000 | 27 | 3 | 12.50% |
May 15, 1999 | 24 | 0 | - |
May 29, 1998 | 24 | 4 | 20.00% |
May 15, 1997 | 20 | 5 | 33.33% |
Jun 14, 1996 | 15 | -89 | -85.58% |
Mar 31, 1995 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RGEN News
- 11 days ago - Repligen: Ongoing Bioprocessing Market Recovery - Seeking Alpha
- 26 days ago - 908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - Benzinga
- 27 days ago - Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Business Wire
- 5 weeks ago - Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook - Benzinga
- 6 weeks ago - Repligen to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Repligen Launches the CTech™ SoloVPE® PLUS System - GlobeNewsWire